Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.24 +0.85%

+$0.15 today

Market cap
$1.56B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.22M

Average 1.74M

NRIX EBITDA Margin

EBITDA as a percentage of revenue.

Nurix Therapeutics, Inc.NASDAQ: NRIX

EBITDA Margin · Q3 FY2026 · quarter ended Aug 2026

EBITDA Margin widens to 84.0%

EBITDA Margin was 84.0% in Q3 FY2026, up 1115.5 pp from a year earlier. On a trailing-twelve-month basis it was 46.0%, up 315.4 pp year over year. Over 3 fiscal years it widened by 147.4 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 66.1% for the fiscal year ending Nov 2026, up from -291.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterAug 2026
84.0%+1034.6 pp QoQ
Last fiscal yearNov 2025
-291.5%+32.7 pp YoY
LTMAug 2026
46.0%+315.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1115.5 pp+409.9 pp-705.6 pp
1 year+32.7 pp+357.6 pp+324.9 pp
3 years+147.4 pp+256.6 pp+109.2 pp
5 years+274.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-291.5%
Year-over-year change
+32.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NRIX compares with its peers on the latest reported figures

  • NRIX's LTM Aug 2026 EBITDA Margin of 46.0% is the highest of the 7 companies compared; the peer median is -218.4%.
  • Its year-over-year change of +315.4 pp is the 3rd highest of 7, against a peer median of +82.0 pp.
  • Over three fiscal years its change of +147.4 pp compares with a peer median of +101.4 pp.
NRIX Competitors Peer median
EBITDA Margin for NRIX and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202646.0% +315.4 pp+147.4 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202643.8% +19.9 pp+89.5 pp
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-74.8% +669.1 pp—
TNGXTango Therapeutics, Inc.FY2025-159.2% +144.1 pp+269.3 pp
KYMRKymera Therapeutics, Inc.LTM Jun 2026-277.6% +319.7 pp-449.2 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-287.9% -44.6 pp+113.4 pp
KURAKura Oncology, Inc.LTM Mar 2026-408.0% -146.3 pp—
RVMDRevolution Medicines, Inc.FY2025— ——
Peer median (excluding NRIX) -218.4%+82.0 pp+101.4 pp

Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Revenue29.75M38.63M76.99M54.55M83.98M
Cost of Revenue116.43M184.5M189.15M221.63M18.86M
Gross Profit(86.68M)(145.87M)(112.16M)(167.08M)65.12M
Gross Margin-291.4%-377.6%-145.7%-306.3%77.5%
Research & Development116.43M184.5M189.15M221.63M308.16M
Selling, General & Admin31.2M38M42.9M45.94M52.74M
Operating Expenses31.2M38M42.9M45.94M350.79M
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
EBITDA(110.98M)(169.55M)(130.29M)(176.87M)(244.84M)
EBITDA Margin-373.0%-438.9%-169.2%-324.2%-291.5%
Operating Income(117.89M)(183.87M)(155.06M)(213.03M)(285.67M)
Operating Margin-396.3%-476.0%-201.4%-390.5%-340.2%
Interest Income823K3.51M11.12M19.73M21.97M
Interest Expense00000
Other Income / Expenses823K3.51M11.12M19.73M21.97M
Income Before Tax(117.06M)(180.36M)(143.95M)(193.3M)(263.7M)
Pre-Tax Margin-393.5%-466.9%-187.0%-354.4%-314.0%
Income Tax Expense131K00270K760K
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Net Margin-393.9%-466.9%-187.0%-354.9%-314.9%
EPS (Basic)(2.73)(3.71)(2.65)(2.88)(3.05)
EPS (Diluted)(2.73)(3.71)(2.65)(2.88)(3.05)
Weighted Avg Shares42.9M48.61M54.34M67.12M86.67M
Weighted Avg Shares (Diluted)42.9M48.61M54.34M67.12M86.67M

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Intrinsic Alpha fair value

Locked

Current Price

$14.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.